Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX Proceeds From Sale Of Short Term Investments

Proceeds From Sale Of Short Term Investments at other companies

Monolithic Power Systems logo
Monolithic Power SystemsMPWR
$14.44M-89.8%
CSX logo
CSXCSX
$5M-92.5%
Southern Copper logo
Southern CopperSCCO
$423.58M+75.4%
FedEx logo
FedExFDX
$27.5M+189%
Advanced Micro Devices logo
Advanced Micro DevicesAMD
$126M+282%
Electronic Arts logo
Electronic ArtsEA
$42M-87.2%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-14.5%
Enterprise value$1.21B+2.6%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s proceeds from sale of short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s proceeds from sale of short term investments?
Pacira BioSciences, Inc. (PCRX) reported proceeds from sale of short term investments of $22.5M in Q1 2026.
How has Pacira BioSciences, Inc.'s proceeds from sale of short term investments changed year-over-year?
Pacira BioSciences, Inc.'s proceeds from sale of short term investments decreased by 67.5% year-over-year, from $69.25M to $22.5M.
What is the long-term trend for Pacira BioSciences, Inc.'s proceeds from sale of short term investments?
Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s proceeds from sale of short term investments has grown at a -28.9% compound annual growth rate (CAGR), from $1.07B to $273.81M.